A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Immunoglobulin Light Chain (AL) Amyloidosis Receiving Etentamig (ABBV-383) as an Intravenous (IV) Infusion

Sylvester Comprehensive Cancer Center - University of Miami /ID# 255856, Miami, Florida, United States

Boston Medical Center /ID# 255066, Boston, Massachusetts, United States

Mayo Clinic - Rochester /ID# 255258, Rochester, Minnesota, United States

Icahn School of Medicine at Mount Sinai /ID# 255408, New York, New York, United States

Columbia University Medical Center /ID# 255068, New York, New York, United States

Memorial Sloan Kettering Cancer Center-Koch Center /ID# 255073, New York, New York, United States

Atrium Health Levine Cancer Institute /ID# 255074, Charlotte, North Carolina, United States

Atrium Health Wake Forest Baptist Medical Center /ID# 255851, Winston-Salem, North Carolina, United States

Oregon Medical Research Center /ID# 255119, Portland, Oregon, United States

Vanderbilt University Medical Center. /ID# 273510, Nashville, Tennessee, United States

University of Washington /ID# 261581, Seattle, Washington, United States

Wisconsin Medical Center /ID# 255836, Milwaukee, Wisconsin, United States

Westmead Hospital /ID# 255200, Westmead, New South Wales, Australia

Princess Alexandra Hospital /ID# 255202, Woolloongabba, Queensland, Australia

Box Hill Hospital /ID# 255199, Box Hill, Victoria, Australia

CHU Limoges - Dupuytren 1 /ID# 255370, Limoges, Franche-Comte, France

CHU Toulouse - Hopital Rangueil /ID# 255377, Toulouse, Haute-Garonne, France

Alexandra General Hospital /ID# 255542, Athens, Attica, Greece

IRCCS AOU di Bologna Policlinico Sant Orsola Malpighi /ID# 255654, Bologna, Italy

Fondazione IRCCS Policlinico San Matteo /ID# 255655, Pavia, Italy

Nagoya City University Hospital /ID# 256086, Nagoya, Aichi-ken, Japan

Kumamoto University Hospital /ID# 262579, Kumamoto, Kumamoto, Japan

Japanese Red Cross Medical Center /ID# 256083, Shibuya-ku, Tokyo, Japan